China's military has approved a coronavirus vaccine developed by its own research staff and a Chinese biotech firm, it was announced on Monday. The vaccine was given the green light for use by troops after trials proved it was both safe and effective, said CanSino Biologics, the biotech firm involved. However, its use for the time being will be restricted to military personnel, who offer a tighter medical control group than the general public. The vaccine candidate, named Ad5-nCoV, was developed jointly by CanSino and the Beijing Institute of Biotechnology in the Academy of Military Medical Sciences. It has been in development since March. CanSino said the results showed the vaccine candidate has potential to prevent diseases caused by the coronavirus, which has killed half a million people globally. The company added that it was not yet possible to say if it could be a commercial success, which would depend on being able to produce the vaccine cheaply as well as safely.
The South Pole has warmed three times faster than the rest of the planet in the last 30 years due to warmer tropical ocean temperatures, new research showed Monday. Antarctica’s temperature varies widely according to season and region, and for years it had been thought that the South Pole had stayed cool even as the continent heated up. Researchers in New Zealand, Britain and the United States analysed 60 years of weather station data and used computer modelling to show what was causing the accelerated warming. Posts from the same category: China scrambles to contain 'strengthening' virus PHOTOS: China marks […]
China's military has approved a coronavirus vaccine developed by its own research staff and a Chinese biotech firm, it was announced on Monday. The vaccine was given the green light for use by troops after trials proved it was both safe and effective, said CanSino Biologics, the biotech firm involved. However, its use for the time being will be restricted to military personnel, who offer a tighter medical control group than the general public. The vaccine candidate, named Ad5-nCoV, was developed jointly by CanSino and the Beijing Institute of Biotechnology in the Academy of Military Medical Sciences. It has been in development since March. CanSino said the results showed the vaccine candidate has potential to prevent diseases caused by the coronavirus, which has killed half a million people globally. The company added that it was not yet possible to say if it could be a commercial success, which would depend on being able to produce the vaccine cheaply as well as safely.
